Allergan’s Mixed R&D News Gives It A Shot In The Eye
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Allergan announced plans to initiate a Phase III clinical trial for its macular degeneration candidate DARPin and FDA approval of a new indication for the eye drug Ozurdex, but FDA also declined to approve Semprana for migraine.
You may also be interested in...
Allergan's Abicipar Effective With Fewer Injections, But More Inflammation In AMD
Allergan and Molecular Partners said dosing of the VEGF inhibitor every eight or 12 weeks was non-inferior to Lucentis every four weeks. But while AMD patients would enjoy fewer sharp pokes in the eye, about 15% may experience inflammation – at least until a new formulation is available.
Valeant Clears Decks, Ups Offer For Allergan – And Says B&L Offers Good Blueprint For Integration
Valeant touted the successes of the B&L acquisition in an effort to prove an Allergan integration would be just as seamless. The increased offer to Allergan came on the heels of Valeant selling its dermatological fillers business to Nestle for $1.4 billion, a move that paves the way for integrating Allergan’s similar portfolio.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.